Derya Ozyörük1, Emine Zengin. 1. Department of Pediatric Hematology and Oncology, The Ministry of Health, Şanlıurfa Children's Hospital, Şanlıurfa, 63000, Turkey, dozyoruk@yahoo.com.
Abstract
OBJECTIVES: To evaluate laboratory and radiological features of hemangiomas in childhood in addition to efficacy and safety of propranolol as a first-line treatment of complicated hemangiomas retrospectively. METHODS: The files of 60 patients who were diagnosed as capillary hemangioma were evaluated retrospectively. Fourteen children with complicated hemangiomas treated with propranolol were analysed, in terms of side effects, efficacy and duration of treatment. RESULTS: These fourteen patients (23 %) were treated with propranolol because of ulcerated, infected and/or deep seated localisations. The duration of treatment with propranolol were between 3 and 12 mo (median: 6 mo). Bronchospasm was observed in one patient during treatment. Except for two patients, all of them responded to propranolol treatment with limited side effects. CONCLUSIONS: The present results support that propranolol is safe and effective treatment choice for complicated infantile hemangiomas, because of minimal side effects and encouraging response rates (80 %). In addition, the authors suggest that routine cranial radiological imagings might not be necessary for hemangiomas without any neurological symptoms.
OBJECTIVES: To evaluate laboratory and radiological features of hemangiomas in childhood in addition to efficacy and safety of propranolol as a first-line treatment of complicated hemangiomas retrospectively. METHODS: The files of 60 patients who were diagnosed as capillary hemangioma were evaluated retrospectively. Fourteen children with complicated hemangiomas treated with propranolol were analysed, in terms of side effects, efficacy and duration of treatment. RESULTS: These fourteen patients (23 %) were treated with propranolol because of ulcerated, infected and/or deep seated localisations. The duration of treatment with propranolol were between 3 and 12 mo (median: 6 mo). Bronchospasm was observed in one patient during treatment. Except for two patients, all of them responded to propranolol treatment with limited side effects. CONCLUSIONS: The present results support that propranolol is safe and effective treatment choice for complicated infantile hemangiomas, because of minimal side effects and encouraging response rates (80 %). In addition, the authors suggest that routine cranial radiological imagings might not be necessary for hemangiomas without any neurological symptoms.
Authors: F Manunza; S Syed; B Laguda; J Linward; H Kennedy; K Gholam; M Glover; A Giardini; J I Harper Journal: Br J Dermatol Date: 2010-01-06 Impact factor: 9.302
Authors: Christine Léauté-Labrèze; Eric Dumas de la Roque; Thomas Hubiche; Franck Boralevi; Jean-Benoît Thambo; Alain Taïeb Journal: N Engl J Med Date: 2008-06-12 Impact factor: 91.245
Authors: Cynthia J Price; Carol Lattouf; Bertha Baum; Michael McLeod; Lawrence A Schachner; Ana M Duarte; Elizabeth Alvarez Connelly Journal: Arch Dermatol Date: 2011-08-15
Authors: Véronique Sans; Eric Dumas de la Roque; Jérôme Berge; Nicolas Grenier; Franck Boralevi; Juliette Mazereeuw-Hautier; Dan Lipsker; Elisabeth Dupuis; Khaled Ezzedine; Pierre Vergnes; Alain Taïeb; Christine Léauté-Labrèze Journal: Pediatrics Date: 2009-08-10 Impact factor: 7.124